

Dabigatran PBS listing expected

A SEPTEMBER PBS listing is expected for dabigatran (Pradaxa), more than two years after it was first recommended for reimbursement.

A spokesperson for manufacturer Boehringer Ingelheim said they were “extremely confident” it would be listed on 1 September for stroke prevention in patients with non-valvular atrial fibrillation.

A spokesperson for the health department could not confirm the date.

BMS and Pfizer, sponsors of competitor apixaban (Eliquis), also said they were confident of securing a 1 September listing.

Bayer’s competitor product, rivaroxaban (Xarelto), will be listed for the indication on 1 August.

Dabigatran was first PBAC recommended in March 2011.